Staphylococcal osteomyelitis is a complex, costly disease that is difficult to treat, with high failure rates and often poor outcomes (1, 2). Staphylococci form biofilms and survive intracellularly, compromising the activity of traditional antibiotics, often requiring debridement/resection of infected and necrotic tissue (2–7). There is an unmet need for more effective, rapidly bactericidal treatments, including those that can be used with standard of care (SOC) therapeutics.
No takes yet. Share an insight, caveat, or question.
Karau et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: